Fort Sheridan Advisors LLC trimmed its stake in shares of Novartis AG (NYSE:NVS – Get Rating) by 3.1% during the first quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 5,647 shares of the company’s stock after selling 180 shares during the period. Fort Sheridan Advisors LLC’s holdings in Novartis were worth $496,000 as of its most recent SEC filing.
Several other hedge funds and other institutional investors have also recently added to or reduced their stakes in NVS. Dimensional Fund Advisors LP increased its stake in Novartis by 35.0% in the 4th quarter. Dimensional Fund Advisors LP now owns 3,870,136 shares of the company’s stock valued at $338,521,000 after buying an additional 1,003,235 shares during the last quarter. Cullen Capital Management LLC increased its stake in shares of Novartis by 17.6% during the 1st quarter. Cullen Capital Management LLC now owns 3,295,271 shares of the company’s stock worth $289,160,000 after purchasing an additional 492,643 shares during the last quarter. Fisher Asset Management LLC boosted its holdings in shares of Novartis by 4.7% during the 1st quarter. Fisher Asset Management LLC now owns 10,871,033 shares of the company’s stock worth $953,933,000 after buying an additional 486,367 shares during the period. Renaissance Technologies LLC boosted its holdings in shares of Novartis by 12.7% during the 4th quarter. Renaissance Technologies LLC now owns 3,727,570 shares of the company’s stock worth $326,051,000 after buying an additional 420,333 shares during the period. Finally, Boston Partners boosted its holdings in shares of Novartis by 6.7% during the 4th quarter. Boston Partners now owns 4,677,403 shares of the company’s stock worth $409,194,000 after buying an additional 292,854 shares during the period. 9.40% of the stock is currently owned by institutional investors and hedge funds.
Novartis Price Performance
NVS stock opened at $85.57 on Friday. The company has a 50 day simple moving average of $85.04 and a 200 day simple moving average of $86.61. The stock has a market cap of $189.33 billion, a price-to-earnings ratio of 8.36, a P/E/G ratio of 2.41 and a beta of 0.51. Novartis AG has a 1 year low of $79.09 and a 1 year high of $95.17. The company has a debt-to-equity ratio of 0.35, a current ratio of 1.38 and a quick ratio of 1.13.
Wall Street Analysts Forecast Growth
A number of research firms have issued reports on NVS. JPMorgan Chase & Co. boosted their price objective on shares of Novartis from CHF 80 to CHF 81 and gave the company an “underweight” rating in a report on Wednesday, July 20th. Morgan Stanley boosted their price objective on shares of Novartis from CHF 90 to CHF 94 in a report on Friday, May 6th. UBS Group boosted their price objective on shares of Novartis from CHF 85 to CHF 88 and gave the company a “neutral” rating in a report on Wednesday, April 27th. Deutsche Bank Aktiengesellschaft cut their price objective on shares of Novartis from CHF 80 to CHF 75 in a report on Wednesday, June 29th. Finally, raised shares of Novartis from a “hold” rating to a “buy” rating in a report on Thursday, April 14th. Two investment analysts have rated the stock with a sell rating, eight have assigned a hold rating, three have issued a buy rating and one has given a strong buy rating to the stock. According to MarketBeat.com, Novartis presently has a consensus rating of “Hold” and a consensus price target of $87.33.
Novartis AG researches, develops, manufactures, and markets healthcare products worldwide. The company operates through two segments, Innovative Medicines and Sandoz. The Innovative Medicines segment offers prescription medicines for patients and healthcare providers. It also provides ophthalmology, neuroscience, immunology, hepatology, dermatology, respiratory, cardiovascular, renal, and metabolism medicine products.
- Get a free copy of the StockNews.com research report on Novartis (NVS)
- MarketBeat: Week in Review 8/1 – 8/5
- How to Use High Beta Stocks to Maximize Your Investing Profits
- Cronos Group Inc’s Revenues Are Up, Is It Time to Buy?
- Beyond Meat Is Not Beyond Hope, And It’s Cheap
- Why Apple Could Be At All-Time Highs By Year End
Receive News & Ratings for Novartis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Novartis and related companies with MarketBeat.com's FREE daily email newsletter.